Evaluation of Patients with Known or Suspected Heart Disease - Article CABG
Clinical Trial: Evaluation of Patients with Known or Suspected Heart Disease
This study is currently recruiting patients.
In this study researchers will admit and evaluate patients with known or suspected heart disease referred to the Cardiology Branch of the National Heart, Lung, and Blood Institute (NHLBI).
Patients participating in this study will undergo a general medical evaluation, including blood tests, urine, examination, chest x-ray and electrocardiogram (EKG). In addition, patients may be asked to have an echocardiogram (ultrasound scan of the heart) and to perform an exercise stress test.
These tests are designed to assess the types and causes of patient's heart diseases and to determine if they can participate in other, specific research studies.
|Peripheral Artery Disease |
Diabetes and Heart Failure
Renal Artery Stenosis
MedlinePlus related topics: Cardiomyopathy; Coronary Disease; Heart Diseases; Heart Diseases--Prevention; Heart Failure; Kidney Diseases; Pulmonary Hypertension; Vascular Diseases
Study Type: Observational
Study Design: Screening
Official Title: Evaluation of Patients with Known or Suspected Heart Disease (Screening Protocol)
Expected Total Enrollment: 9999
Study start: May 10, 1992
The principal mission of the NIH is the conduct of research that elucidates biological mechanisms, pathogenesis, and treatment of disease. Patients with known or suspected cardiovascular diseases are referred to NHLBI cardiologists for consideration of participation in clinical research protocols. However, eligibility for participation is often uncertain from referral information or even after an outpatient evaluation. The purpose of this protocol is to permit inpatient evaluation of patients for whom participation in clinical research protocols is under consideration in order to determine protocol eligibility by means of conventional laboratory and cardiovascular testing.
Genders Eligible for Study: Both
The following is a representative list of the types of patient presentations and potential diagnoses eligible for this protocol:
1. Coronary artery disease with effort or rest angina or inducible myocardial ischemia as determined by noninvasive testing.
2. Cardiomyopathies including congestive phenotypes.
3. Peripheral artery disease with intermittent claudication or limb-threatening ischemia.
4. Renovascular disease with uncontrolled hypertension, intermittent pulmonary edema, or evidence of ischemic nephropathy.
5. Upper extremity peripheral artery disease.
6. Diabetes, heart failure and pulmonary hypertension.
Pregnancy, for those patients who require catheterization-based diagnostics.
Inability to provide informed consent.
Location and Contact Information
National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike, Bethesda, Maryland, 20892, United States; Recruiting
Detailed Web Page
Record last reviewed: March 18, 2004
Last Updated: March 16, 2005
Record first received: November 3, 1999
ClinicalTrials.gov Identifier: NCT00001313
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Cache Date: April 9, 2005